Peptides News and Research

RSS

ESA Biosciences to launch Corona CAD at Pittcon 2009

ESA Biosciences, Inc., a Magellan Biosciences company and leader in novel HPLC systems that improve results for pharmaceutical development and QA/QC, life science, and analytical-chemistry customers worldwide, will launch a new, ultra-high-performance version of its award-winning Corona CAD at Pittcon 2009.

2 Mar 2009

McGill researcher's radical new green chemistry makes the impossible possible

McGill University chemistry professor Chao-Jun (C.J.) Li is known as one of the world leading pioneers in green chemistry, an entirely new approach to the science which eschews the use of toxic, petrochemical-based solvents in favour of basic substances like water and new ways of making molecules.

24 Feb 2009

Researchers block immune cell rush behind deadly sepsis

Researchers have found a way to block the ability of white blood cells to sprint toward the sites of infection when such speed worsens the damage done by sepsis, the often fatal, whole-body bacterial infection, according to a study published today in the journal Blood.

24 Feb 2009

Targeted nanospheres find, penetrate, then fuel burning of melanoma

Hollow gold nanospheres equipped with a targeting peptide find melanoma cells, penetrate them deeply, and then cook the tumor when bathed with near-infrared light. When heated with lasers, the actively targeted hollow gold nanospheres did eight times more damage to melanoma tumors in mice than did the same nanospheres that gathered less directly in the tumors.

23 Feb 2009

Blood pressure drug losartan may benefit brain tumor patients

A widely used blood pressure medication may be the key to preventing brain function loss common after radiation treatment, according to a newly published study by researchers at Wake Forest University Baptist Medical Center.

20 Feb 2009

GlaxoSmithKline starts phase III trial of Syncria (albiglutide) type 2 diabetes medication

GlaxoSmithKline has announced initiation and dosing of the first patient of the Phase III clinical trial programme to evaluate the efficacy, safety and tolerability of the investigational GLP-1 (Glucagon-like peptide 1) agonist Syncria (albiglutide) in men and women with type 2 diabetes.

18 Feb 2009

New nationwide Alzheimer's study underway

Researchers at Wake Forest University Baptist Medical Center are preparing to begin a clinical trial aimed at testing an investigational new drug that may help control the progression of Alzheimer's disease.

17 Feb 2009

Molecules self-assemble to provide new therapeutic treatments

Researchers in the laboratory of Samuel I. Stupp at Northwestern University have an interesting approach for tackling some major health problems: gather raw materials and then let them self-assemble into structures that can address a multitude of medical needs.

16 Feb 2009

Common gene variants increase risk of hypertension, may lead to new therapies

A new study has identified the first common gene variants associated with an increased incidence of hypertension - a significant risk factor for heart attack, stroke and kidney failure.

16 Feb 2009

Statistical analysis could yield new drug target for multiple sclerosis

An elaborate statistical analysis of genes from more than 7,000 individuals has identified an amino acid that appears to be a major risk factor for multiple sclerosis, a devastating autoimmune disorder that afflicts 2.5 million people worldwide.

15 Feb 2009

Discovery of potential treatment for Rett syndrome

A molecule that promotes brain development could serve as a possible treatment for Rett syndrome, the most common form of autism in girls, according to researchers at MIT's Picower Institute for Learning and Memory and the Whitehead Institute for Biomedical Research.

9 Feb 2009

Peptide loaded gold nanospheres find, penetrate, then fuel burning of melanoma

Hollow gold nanospheres equipped with a targeting peptide find melanoma cells, penetrate them deeply, and then cook the tumor when bathed with near-infrared light, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reported in the Feb. 1 issue of Clinical Cancer Research.

2 Feb 2009

BioGenes as new designated partner in EU funded dementia project

BioGenes GmbH, a specialist in sophisticated antibody development, has been chosen as a new partner of cNEUPRO. cNEUPRO is a EU funded research project to analyse neurodegenerative diseases and discover novel biomarkers, and so improve early and differential diagnosis of Alzheimer's dementia.

2 Feb 2009

Biomarkers as a guide to therapy in heart failure patients

There has been much interest in the biomarker known as N-terminal brain natriuretic peptide (BNP) as a precise guide for the diagnosis, prognosis and treatment of heart failure.

29 Jan 2009

Medarex announces allowance of IND application for antibody-drug conjugate, MDX-1203

Medarex, Inc. has announced the allowance of an investigational new drug (IND) application filed with the U.S. Food & Drug Administration (FDA) for MDX-1203, the Company's first Antibody-Drug Conjugate (ADC) candidate generated from its proprietary technology.

29 Jan 2009

Insight into how Toxoplasma gondii triggers immune response in its host

Researchers provide insight into how Toxoplasma gondii , a common parasite of people and other animals, triggers an immune response in its host.

19 Jan 2009

Three new genetic variations that increase the risk of obesity

The gene variant most strongly associated with childhood obesity and adult morbid obesity in the study is located near the PTER gene, the function of which is not known. This variant is estimated to account for up to a third of all childhood obesity, and a fifth of all cases of adult obesity.

19 Jan 2009

Researchers find essential proteins for final stage of malaria transmission cycle

Researchers at the Johns Hopkins Malaria Research Institute (JHMRI) have identified, for the first time, the molecular components that enable the malaria-causing parasite Plasmodium to infect the salivary glands of the Anopheles mosquito-a critical and final stage for spreading malaria to humans.

19 Jan 2009

E. coli persists against antibiotics through HipA-induced dormancy

Bacteria hunker down and survive antibiotic attack when a protein flips a chemical switch that throws them into a dormant state until treatment abates, researchers at The University of Texas M. D. Anderson Cancer Center report in the Jan.16 edition of Science.

19 Jan 2009

Artificial antibody delivers nanoparticles to tumors

Antibodies that target epidermal growth factor receptor (EGFR) have proven themselves as potent anticancer drugs. Now, a team of investigators led by Shuming Nie, Ph.D., and Lily Yang, Ph.D., both at the Emory University School of Medicine and members of the Emory-Georgia Tech Nanotechnology Center for Personalized and Predictive Oncology, is aiming to capitalize on this targeting ability, using a modified anti-EGFR antibody to delivery nanoparticles into tumor cells.

18 Jan 2009